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The ﬁ ndings of the Cognitive Functioning and Ageing 
Study (CFAS) I and II are unequivocally good news. New 
data, reported in The Lancet,1 suggest that the prevalence 
of dementia in the UK in 2011 was signiﬁ cantly lower 
than would have been expected based on the estimated 
prevalence in 1991. For CFAS I, data were taken from 
three geographical areas—Cambridgeshire, Newcastle, 
and Nottingham—to generate an estimate of the 
prevalence of dementia in the UK in 1991. This was based 
on a randomly selected sample of 7635 people aged 
65 years and older interviewed in these areas, with 1457 
being diagnostically assessed for dementia. An algorithmic 
diagnostic approach was used so that the resulting esti-
mate, which was standardised to the 1991 population 
structure, could be compared with future results. For CFAS 
II, investigators used an identical diagnostic method to 
estimate the prevalence of dementia in the UK in 2011. On 
the basis of the age and sex speciﬁ c prevalence estimates 
from CFAS I, 664 000 individuals were estimated to have 
dementia in 1991. After applying the eﬀ ects of population 
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government. We must develop the evidence base 
on child health, particularly for early intervention, 
including the Healthy Child Programme, and pro-
mote resilience in its widest sense. Further recommen-
dations seek to translate the evidence presented in 
the Annual Report into practical actions, which include 
commissioning age-appropriate training for health 
professionals, translating the evidence on children 
and young people’s views of health care into a “Health 
Deal”(panel 2), and developing tool kits for schools 
to improve educational attain ment through Personal 
Social Health and Economic (PSHE) education. We 
badly need independent monitoring of pro gress 
against outcome indicators.11
This report is not unprecedented. Much has been 
written about the state of child health in the UK,12–14 
and children are championed by front-line staﬀ  and 
many groups in civil society, as well as the Children’s 
Commissioner. The experts who contributed to this 
report drew together the contemporary scientiﬁ c 
evidence, and we combine this with new economic 
analyses to make a powerful case for focusing anew 
everyone’s eﬀ orts on children and young people. 
Economic realities alongside the rising health-care 
demands for an ageing population make improvement 
in this area challenging. But this report shows that 
prevention can pay. Our children deserve better.
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ageing to this estimate, the number of people with 
dementia was projected to be 884 000 in 2011. However, 
extrapolation of the results of CFAS II suggests that the 
number of people with dementia in 2011 was 670 000, a 
decrease in prevalence from 8·3% in 1991 to 6·5% in 2011 
(OR for CFAS I vs CFAS II 0·7; 95% CI 0·6–0·9). Importantly, 
the study’s greatest strengths are in its relative estimates 
of changes between phases rather than its absolute 
estimates of numbers. As with any research criteria, the 
diagnostic system used in this study has limitations, as 
acknowledged by the authors. The low response rate 
(56% vs 80% for the ﬁ rst phase) for the second phase 
might also be a source of error. Even with the adjustments 
and modelling made, it remains entirely possible that 
there is a substantial response bias, which might have a 
substantive eﬀ ect on the prevalence estimates. 
However, these data do suggest that things that the 
population has done have decreased the age-speciﬁ c 
incidence of dementia, and therefore the number of 
people with dementia is lower than it would have been 
without our making these changes. The adage asserted in 
England’s National Dementia Strategy2 that “what’s good 
for your heart is good for your head” therefore seems 
to be supported by the new evidence presented. It is 
plausible that changes in health behaviour and provision, 
including smoking cessation and improved manage-
ment of cardiovascular risk factors such as hypertension, 
have prevented or delayed the onset of dementia at a 
population level. The next questions must be: how much 
further can we go in pursuit of this preventive agenda? 
How many more cases can be prevented? What do we 
need to do to have the greatest eﬀ ect? These questions 
need empirical investigation followed by purposeful 
strategy formulation and implementation.
A powerful message from these data1 is that what we as 
individuals and services do matters in terms of dementia. 
The CFAS data point to substantial added value from 
exist ing healthy lifestyle messages. They suggest that 
life style changes—eg, in diet, exercise, and smoking—
might reduce the risk of dementia and promote more 
general health and wellbeing. This notion should be 
incorporated into health promotion messaging. Inclusion 
of the potential beneﬁ t of dementia prevention in com-
munications could drive greater adoption of healthy life-
styles with resulting beneﬁ ts for individuals and society. 
This is a message of empowerment, but it comes with 
a warning. As with all investments, in this investment in 
health, positive past performance does not always predict 
future gains. Thus, a need exists for caution in prediction 
of the future numbers with dementia. If positive changes 
in health behaviour can decrease prevalence of dementia, 
then negative lifestyle choices might promote, rather 
than prevent, dementia. The cohorts of people who 
have been developing dementia in the past 30 years 
lived through periods of austerity during which diet was 
often controlled and this might have protected them 
in the balance of risk. This was not the case for present 
cohorts entering the period of risk for dementia (ie, those 
aged >60 years). It is plausible that the present epidemic 
of morbid obesity, with consequent cardiovascular 
disorders, stroke, and diabetes, might act to increase the 
proportion of people with dementia in future cohorts. 
What these data do not mean is that dementia should 
be any less of a priority. Even with the changes described 
by Fiona Matthews and colleagues,1 dementia remains 
very common, very expensive, and profoundly negative in 
its eﬀ ects on people with the disorder and their families.2 
Even with a small decrease in incidence and prevalence, 
population ageing will still double the numbers with 
dementia worldwide in the next generation.3 Dementia 
remains one of the greatest challenges faced by health-
care and social-care systems worldwide, in low-income 
and middle-income countries as well as in more 
developed economies.4 Dementia is one of the very 
few health disorders that in itself has a macroeconomic 
eﬀ ect,5 driven by the contribution of dementia to long-
term care costs, with at least three quarters of people 
in care homes now having dementia, as shown by the 
CFAS estimates,1 and by people with dementia being 
over-represented in general hospital and emergency 
populations. The existing management of dementia at a 
population and an individual level is improving with the 
execution of national plans and improved individual care.6 
But there remain public and professional misconceptions, 
a low level of diagnosis with more than half of those with 
dementia never identiﬁ ed as such, and discontinuities and 
poor quality care from diagnosis to end of life for many.
Dementia is a powerful example of the complexity 
and long-term nature of the disorders that are now the 
major outstanding challenges for health-care systems. 
Those with dementia are generally an old and frail 
population with multimorbidity; data from the Scottish 
School of Primary Care7 suggest that only 17% of people 
with dementia have no other long-term disorder. If we 
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In The Lancet, Anthony Barnett and colleagues1 pro-
vide evidence that linagliptin, a dipeptidyl peptidase-4 
(DPP4) inhibitor, eﬀ ectively lowered glycated haemo-
globin (HbA1c) in a cohort of 241 older patients (mean 
age 75 years) with type 2 diabetes poorly controlled 
with usual treatments. This randomised, placebo-
con trolled trial was done in a 24-week period; mean 
HbA1c was 7·8% (SD 0·8) at baseline, and at week 24, 
placebo-adjusted mean change in HbA1c with linagliptin 
was –0·64% (95% CI –0·81 to –0·48, p<0·0001). The 
investigators acknowledge the scarcity of speciﬁ c studies 
of glucose-lowering treatments in older patients with 
diabetes and of the DPP4-inhibitor class in particular. 
They pro vide some potential reasons why this class can 
oﬀ er some advantages in treatment of older patients, 
such as a reduced risk of hypoglycaemia and no appre-
ciable weight gain. Additionally, they argue that it is 
important to consider the special issues of medical co-
morbidities and frailty in older patients in trials of this 
kind. The Lancet, perhaps in recognition of this shortfall 
in the medical literature, also published a similar study 
of the DPP4 inhibitor vildagliptin in a group of older 
patients with type 2 diabetes.2
The study by Barnett and colleagues1 was well 
designed and powered to show a clinically meaningful, 
signiﬁ cant diﬀ erence in HbA1c in the groups studied, 
without an increased risk of hypoglycaemia. In general, 
the patients studied had levels of duration of diabetes 
and renal impairment commonly noted in older 
patients with this disorder. The investigators accept 
the limitations of this type of pharma-directed, short 
duration study. Longer-term monitoring data are 
needed to ensure safety of patients.
This study, however, missed crucial opportunities 
to provide increased insight into the management of 
Frailty and diabetes
can get services right for dementia, then we will be a 
long way towards getting them right for all individuals 
with complex and long-term disorders. The CFAS results 
suggest that prevention is possible and that we can have 
agency in this most complex of disorders. These ﬁ ndings 
should spur us on, to go further and faster in secondary 
and tertiary prevention as well as primary prevention in 
dementia, for the beneﬁ t of all. This study shows that 
we can all make a diﬀ erence.
Sube Banerjee
Brighton and Sus sex Medical School, University of Sussex, 
Brighton BN1 9RY, UK
s.banerjee@bsms.ac.uk
I declare that I have no conﬂ icts of interest.
1 Matthews FE, Arthur A, Barnes LE, et al, on behalf of the Medical Research 
Council Cognitive Function and Ageing Collaboration. A two-decade 
comparison of prevalence of dementia in individuals aged 65 years and 
older from three geographical areas of England: results of the Cognitive 
Function and Ageing Study I and II. Lancet 2013; published online July 16. 
http://dx.doi.org/S10140-6736(13)61570-6.
2 Department of Health. Living well with dementia: a national dementia 
strategy. 2009. https://www.gov.uk/government/publications/living-well-
with-dementia-a-national-dementia-strategy (accessed July 16, 2013).
3 Alzheimer’s Disease International. World Alzheimer report 2009. http://www.
alz.co.uk/research/ﬁ les/WorldAlzheimerReport.pdf (accessed July 16, 2013).
4 World Health Organization, Alzheimer’s Disease International. Dementia: 
a public health priority. 2012. http://www.who.int/mental_health/
publications/dementia_report_2012/en/ (accessed July 16, 2013).
5 Banerjee S. The macroeconomics of dementia—will the world economy get 
Alzheimer’s disease? Arch Med Res 2012; 43: 705–09.
6 Banerjee S. Living well with dementia—development of the National 
Dementia Strategy for England. Int J Geriatr Psychiatry 2010; 25: 917–25.
7 Barnett K, Mercer S, Norbury M, Watt G, Wyke S, Guthrie B. The epidemiology 
of multimorbidity in a large cross-sectional dataset: implications for health 
care, research and medical education. Lancet 2012; 380: 37–43.
Panel: Future research in diabetes mellitus and frailty
Application of the frailty concept to diabetes
• Role of frailty in the comorbid illness of diabetes
• The distinct pathophysiology of frailty compared with the disabling eﬀ ect of 
vascular complications
Applicability of frailty assessment instruments in routine clinical practice
• Modiﬁ cation of and adapting current instruments to an outpatient or care home setting
• Acceptance of proxy measures of frailty where service design is less developed
• Testing the rapid FRAIL screen (fatigue, inability to walk a block or climb a ﬂ ight of stairs, 
numbers of illnesses, and 5% loss of weight in 6 months) in people with diabetes
Development of clinical trial methods
• Instigate randomised clinical trials to examine beneﬁ ts using appropriate primary 
and secondary outcome measures such as disability, cognitive dysfunction, frailty, 
and quality of life
• Use of a study design that allows enhanced uptake of interventions in primary care
Inﬂ uencing commissioners of clinical diabetes services
• Health economic analyses of interventions
• Study designs that allow relevant and appropriate cost comparisons
• Demonstration of likely beneﬁ ts in a broad range of older people with frailty and diabetes
Based on a design by Mohandas and colleagues, 2011.13 
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